198 related articles for article (PubMed ID: 38429759)
1. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
[TBL] [Abstract][Full Text] [Related]
2. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A; Molla A; Nicolini G; Perotti VE; Sgambelluri F; Covre A; Fazio C; Lofiego MF; Di Giacomo AM; Coral S; Manca A; Sini MC; Pisano M; Noviello T; Caruso F; Brich S; Pruneri G; Maurichi A; Santinami M; Ceccarelli M; Palmieri G; Maio M; Mortarini R;
J Exp Clin Cancer Res; 2022 Nov; 41(1):325. PubMed ID: 36397155
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.
Lofiego MF; Cannito S; Fazio C; Piazzini F; Cutaia O; Solmonese L; Marzani F; Chiarucci C; Di Giacomo AM; Calabrò L; Coral S; Maio M; Covre A; On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators
Epigenomes; 2021 Dec; 5(4):. PubMed ID: 34968251
[TBL] [Abstract][Full Text] [Related]
4. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
Front Immunol; 2022; 13():819515. PubMed ID: 35251000
[TBL] [Abstract][Full Text] [Related]
5. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
7. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.
Fazio C; Covre A; Cutaia O; Lofiego MF; Tunici P; Chiarucci C; Cannito S; Giacobini G; Lowder JN; Ferraldeschi R; Taverna P; Di Giacomo AM; Coral S; Maio M
Front Pharmacol; 2018; 9():1443. PubMed ID: 30581389
[TBL] [Abstract][Full Text] [Related]
9. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
10. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of CCL2 in the prognosis and immunotherapy response of glioblastoma multiforme.
Deng L; Ren J; Li B; Wang Y; Jiang N; Wang Y; Cui H
BMC Genomics; 2023 Dec; 24(1):746. PubMed ID: 38057698
[TBL] [Abstract][Full Text] [Related]
12. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
Front Immunol; 2022; 13():820673. PubMed ID: 35309323
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
Chin C; Lunking ES; de la Fuente M; Ayad NG
Front Oncol; 2018; 8():521. PubMed ID: 30483476
[TBL] [Abstract][Full Text] [Related]
15. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
17. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
19. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells.
Qiu Z; Zhao L; Shen JZ; Liang Z; Wu Q; Yang K; Min L; Gimple RC; Yang Q; Bhargava S; Jin C; Kim C; Hinz D; Dixit D; Bernatchez JA; Prager BC; Zhang G; Dong Z; Lv D; Wang X; Kim LJY; Zhu Z; Jones KA; Zheng Y; Wang X; Siqueira-Neto JL; Chavez L; Fu XD; Spruck C; Rich JN
Cancer Discov; 2022 Feb; 12(2):502-521. PubMed ID: 34615656
[TBL] [Abstract][Full Text] [Related]
20. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]